Clinical trial
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With…
NCT00419744 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00419744 |
|---|---|
| Title | A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD |
| Official title | A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease |
| Intervention type | Drug |
| Interventions | Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler |
| Enrollment | 1,200 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jan 9, 2007 |
| Last update posted | Sep 16, 2010 |
| Countries | Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, United States, Venezuela |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: